Next Article in Journal
Science, Innovation and Education as Pillars of High-Quality Implant Dentistry: Overcoming Challenges through Innovation Dictates Trends
Next Article in Special Issue
Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model
Previous Article in Journal
Novel Insights into the Role of UBE3A in Regulating Apoptosis and Proliferation
Previous Article in Special Issue
Strategies to Improve Participation of Older Adults in Cancer Research
Open AccessReview

Managing Bladder Cancer Care during the COVID-19 Pandemic Using a Team-Based Approach

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(5), 1574;
Received: 14 April 2020 / Revised: 18 May 2020 / Accepted: 19 May 2020 / Published: 22 May 2020
The recent novel coronavirus, named coronavirus disease 2019 (COVID-19), has developed into an international pandemic affecting millions of individuals with hundreds of thousands of deaths worldwide. The highly infectious nature and widespread prevalence of this disease create a new set of obstacles for the bladder cancer community in both delivering and receiving care. In this manuscript, we address the unique issues regarding treatment prioritization for the patient with bladder cancer and how we at City of Hope have adjusted our clinical practices using a team-based approach that utilizes shared decision making with all stakeholders (physicians, patients, caregivers) to optimize outcomes during this difficult time. In addition to taking standard precautions for minimizing COVID-19 risk of exposure for those entering a healthcare facility (screening all personnel upon entry and donning facemasks at all times), we suggest the following three measures: (1) delay post-treatment surveillance visits until there is a decrease in local COVID-19 cases, (2) continue curative intent treatments for localized bladder cancer with COVID-19 precautions (i.e., choosing gemcitabine/cisplatin (GC) over dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC) neoadjuvant chemotherapy), and (3) increase the off-treatment period between cycles of palliative systemic therapy in metastatic urothelial carcinoma patients. View Full-Text
Keywords: bladder cancer; urothelial carcinoma; COVID-19; team-based medicine bladder cancer; urothelial carcinoma; COVID-19; team-based medicine
Show Figures

Figure 1

MDPI and ACS Style

Wang, T.; Liu, S.; Joseph, T.; Lyou, Y. Managing Bladder Cancer Care during the COVID-19 Pandemic Using a Team-Based Approach. J. Clin. Med. 2020, 9, 1574.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop